Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1604-1609
doi: 10.1161/hq1001.096645
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vermeersch, P.
Right arrow Articles by Janssens, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vermeersch, P.
Right arrow Articles by Janssens, S.
Related Collections
Right arrow Restenosis
Right arrow Animal models of human disease
Right arrow Gene therapy
Right arrow Endothelium/vascular type/nitric oxide
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1604.)
© 2001 American Heart Association, Inc.


Vascular Biology

L-Arginine Administration Reduces Neointima Formation After Stent Injury in Rats by a Nitric Oxide-Mediated Mechanism

P. Vermeersch; Z. Nong; E. Stabile; O. Varenne; H. Gillijns; M. Pellens; N. Van Pelt; M. Hoylaerts; I. De Scheerder; D. Collen; S. Janssens

From the Center for Transgene Technology and Gene Therapy (P.V., Z.N., E.S., O.V., H.G., M.P., M.H., D.C.), Flanders Interuniversity Institute for Biotechnology, and the Department of Cardiology (N.V.P., I.D.S., S.J.), University of Leuven, Leuven, Belgium.

Correspondence to Stefan Janssens, MD, PhD, Center for Transgene Technology and Gene Therapy, 49 Herestraat, B-3000 Leuven, Belgium. E-mail stefan.janssens{at}med.kuleuven.ac.be

Abstract— The clinical outcome of vascular stenting is limited by in-stent stenosis. Increased nitric oxide (NO)/cGMP signaling by L-arginine (L-Arg) supplementation, the substrate for NO synthase (NOS), or NOS gene transfer may reduce in-stent neointima formation. After stenting, vascular cell proliferation in rat carotid arteries, as measured by 5'-bromodeoxyuridine (5'-BrdU) incorporation, indicated 15±8%, 28±5%, and 33±7% 5'-BrdU-positive vascular cells at 4, 7, and 14 days, respectively. Reporter ß-galactosidase gene transfer efficacy was evidenced by 30% ß-galactosidase-expressing medial smooth muscle cells at 14 days. The intima-to-media ratio (I/M) progressively increased to 2.32±0.24 at 14 days. To target in-stent neointima formation, animals were infected with adenoviral vectors (4x1010 plaque-forming units per mL) expressing NOS2 (AdNOS2) or no transgene (AdRR5), or they received daily doses of L-Arg (500 mg · kg-1 · d-1 IP). The neointima at 14 days was smaller in L-Arg-treated than in untreated rats (I/M 1.25±0.35 vs 2.32±0.24, P<0.05, n=7 each) or in AdRR5- and AdNOS2-infected rats (I/M 2.57±0.43, n=7 and 1.82±0.75, n=8, respectively; P<0.05 for both). The effect of L-Arg was abolished by simultaneous administration of NG-nitro L-arginine methyl ester, an NOS inhibitor (2.03±0.39, P<0.05, vs L-Arg). Inflammation was markedly less in L-Arg- and AdNOS2-treated than in AdRR5-infected rats. Supplemental L-Arg reduces neointima formation after stenting by way of an NOS-dependent mechanism and may be a valuable strategy to target in-stent stenosis.


Key Words: arginine • neointima formation • gene therapy • stents • nitric oxide synthase